CEO & President
Mr. Mesa is a highly experienced drug delivery and pharmaceutical product development executive. Mr. Mesa was a key figure in the development of the EpiPen® Auto-injector and is a named inventor on multiple U.S. and foreign patents and patent applications. He has successfully managed multiple auto-injector development programs for emergency medical situations for both the private and government sectors. This includes treatments delivered by auto-injector for seizures attributed to nerve agent exposure as well as epilepsy. Mr. Mesa developed a benzodiazepine auto-injector used in the NIH-sponsored RAMPART Study and the King Pharmaceuticals’ RESCUE Study to treat epileptic seizures in humans.
Kenneth Dretchen Ph.D.
Vice President & Chief Scientific Officer
Dr. Dretchen is the highly published former Dean of Research, Professor and Chairman of the Department of Pharmacology and Physiology at Georgetown University Medical Center. Previously at Georgetown University, Dr. Dretchen had direct responsibility for the Animal Care and Use Committee, the Institutional Review Board, Radiation Safety and all research involving biohazards. Dr. Dretchen served as a consulting pharmacologist for King Pharmaceuticals on a study involving clinical trials to assess the pharmacokinetics and side effects of a benzodiazepine given intramuscularly via an auto-injector. He has published the results of a study in Epilepsia (31:313-317, 1990) demonstrating the superiority of midazolam compared to diazepam in the control of seizures in a mouse model of Status Epilepticus.
Tim Warneke, MS
Vice President Operations
Mr. Warneke brings over 30 years of pharmaceutical development experience across large to mid-size pharmaceutical companies and the world’s largest contract research organization. He has been responsible for clinical study conduct across all phases of pharmaceutical development and therapeutic areas including the use of a caregiver-administered treatment of cluster seizures in children and adults with epilepsy using an auto-injector. Mr. Warneke has leveraged his expert knowledge of the Code of Federal Regulations, ICH Guidelines, Good Clinical Practice and Good Laboratory Practice to provide operational excellence in support of numerous Investigational New Drug and New Drug Applications.
Brian has been a partner of Domain since 1988, where he has led innovative investments in life sciences companies. Since joining Domain, he has served on the board of directors of more than 35 private and public companies and has been chairman of six.
Brian has been a partner of Domain since 1988, where he has led innovative investments in life sciences companies. Since joining Domain, he has served on the board of directors of more than 35 private and public companies and has been chairman of six. He is currently on the board of one public company, REVA Medical.
Prior to Domain, Brian was president of Rorer Group, now a part of Sanofi, where he was the primary architect of a strategy transforming the company from a diversified medical products company to a fully integrated pharmaceutical company, doubling sales with a multi-fold increase in profits. Previous to that, Brian was president of Survival Technology, a start-up medical products company whose sales growth placed it in the top ten of the Inc 100. He received his B.A. in mathematics from Colgate University and his MBA from Harvard Business School.
Brian was former chairman and currently serves on the board of directors of both the Center for Venture Education (Kauffman Fellows Program) and the Wistar Institute, a leader in preclinical bio-medical research in the non-profit sector. He is also a member of the Board of Trustees of the La Jolla Playhouse.
Brian served as chairman of the National Venture Capital Association. He is a trustee emeritus of Germantown Academy and is a former trustee of the University of Pennsylvania School of Nursing and the Sanford Burnham Prebys Medical Discovery Institute. He is also a former board member of the industry associations representing the medical device industry as well as the association representing consumer pharmaceuticals.
Sherry Scullion, President of the Scullion Strategy Group, LLC, has a long-standing career in innovation strategy, product marketing, product development and product design across a broad scope of industries, with the majority of her career in animal health.
Sherry Scullion, President of the Scullion Strategy Group, LLC, has a long-standing career in innovation strategy, product marketing, product development and product design across a broad scope of industries, with the majority of her career in animal health. She has been involved in the pipeline development, launch and product management of 18 innovative US and global products in the veterinary prescription and OTC markets.
She worked in a variety of marketing, product development and design engineering roles for companies such as Elanco™ Animal Health, Novartis Animal Health, B/E Aerospace (now Rockwell Collins) and Philips Communication & Security Systems (now Bosch Security Systems).
Sherry holds an Executive Certificate in Strategy and Innovation from the Massachusetts Institute of Technology, an MBA with a Marketing Concentration from Wake Forest University, and a Bachelor’s in Mechanical Engineering Technology from the State University of New York College at Buffalo.
Michael Podell DVM
Dr. Podell is a Chief Medical Officer at MedVet and serves as an Adjunct Professor in the Department of Clinical Sciences at the University of Illinois at Champaign and in the Department of Surgery, Section of Neurosurgery, at The University of Chicago School of Medicine.
Michael Podell DVM
Dr. Podell is currently a Chief Medical Officer at MedVet and serves as an Adjunct Professor in the Department of Clinical Sciences at the University of Illinois at Champaign and in the Department of Surgery, Section of Neurosurgery, at The University of Chicago School of Medicine. He is a Diplomate of the American College of Veterinary Internal Medicine in Neurology with a certification in Neurosurgery. He has published over 200 scientific articles, book chapters and proceedings in comparative veterinary neurology and neuroscience and has lectured worldwide. As an active researcher, he has been recognized by the National Institutes of Health with a Research Scientist Career Development Award and the Pfizer Animal Health Award for Research Excellence.